New German medicine reference prices can reduce the recoverable value of pharmacy stock from one effective date to the next. The risk is concentrated in high-cost packs: a small number of units bought before a lower reimbursement limit and supplied afterwards can create a material loss. Pharmacies should therefore treat the September and October 2026 changes as a short-term inventory and liquidity project, not merely as a reimbursement issue.
What is a German medicine reference price?
Under section 35 of Social Code Book V, the reference price is the maximum statutory health-insurance reimbursement for medicines in a defined group. A patient co-payment may arise above this limit if the manufacturer price is not adjusted and no suitable reimbursable alternative is used. Reference prices can be introduced, changed, withdrawn or reapplied.
The price and reimbursement position applicable on the dispensing date determine the pharmacy’s economics; an earlier purchase does not preserve the former recoverable value. Purchase date, dispensing date, manufacturer response, wholesale terms and the real substitution option therefore have to be assessed together.
Effective dates in September and October 2026
The National Association of Statutory Health Insurance Funds documents renewed reference-price application for selected products in two groups from 1 September 2026 and first price setting in eight groups from 1 October 2026. Several reimbursement boundaries will therefore meet existing pharmacy stock within a short period.
The number of groups alone does not determine the financial effect. The affected product codes, current and future reimbursement amounts, expected manufacturer-price changes, stock, open orders, normal stock turnover and return or rebooking options are decisive.
How inventory loss arises
A loss can arise when a pack was acquired at the former price but is dispensed after a lower reimbursement boundary applies, without sufficient supplier credit, return right or manufacturer adjustment.
- The pharmacy buys a pack before the effective date at the previous price.
- A new or lower reimbursement boundary applies from the effective date.
- Manufacturer and market prices may react at different times or by different amounts.
- The pack is dispensed only after the change.
- The difference remains wholly or partly with the pharmacy unless a contract, supplier or manufacturer provides compensation.
The effect is product- and contract-specific. Applying one blanket reduction to all affected medicines would be as inaccurate as assuming that every pack automatically creates a loss.
Why high-cost medicines need pack-level control
Low quantities can tie up substantial working capital. A one-percent price movement on a high-cost medicine may exceed the value of an entire month’s stock of many lower-priced items. Individual prescriptions, limited substitution, postponed appointments and patient-specific procurement can also extend the holding period.
Pharmacies should therefore manage high-cost products by individual product code and pack, not only through general stock coverage. Patient assignment, the next realistic dispensing date, return rights, payment terms, open prescription or approval status and whether an order must really be placed before the effective date all matter.
Eight-step inventory review
- Load affected product codes: align decision data and the merchandise-management system.
- Value the stock: calculate quantity, acquisition value, current price, new boundary and potential euro difference for each product code.
- Review open orders: stop, postpone or limit non-essential inbound stock.
- Forecast dispensing: combine historic demand, confirmed patient needs and realistic stock coverage.
- Separate high-cost packs: assign an owner, prescription status and next decision date to every pack.
- Clarify returns and compensation: document effective-date, price and return arrangements with wholesalers, direct suppliers and manufacturers.
- Adjust replenishment: retain safety stock only where supply and actual demand justify it.
- Reconcile after the change: review prices, co-payments, substitution, credits and residual risk.
Procurement, wholesalers and manufacturers must work in sync
Pharmacies need timely machine-readable product-code and price information, clear return rules and reliable delivery dates. Pharmaceutical wholesalers should segment affected assortments, stock, open orders and customer communication early. Manufacturers should communicate price decisions, availability and possible compensation models in time for every supply-chain stage to act before the effective date.
Incomplete or late data shifts risk to the end of the supply chain. A robust process therefore connects price files, the merchandise-management system, purchasing, inventory lists, supplier contacts and accounting in one effective-date plan.
Do not overlook liquidity and accounting
Inventory losses affect profit and liquidity at different times. Supplier payment may fall due before dispensing, reimbursement, return or credit. Pharmacy management and tax advisers should keep potential write-downs, outstanding supplier credits and effective-date stock traceable.
Related tiger.PHARMA services include procurement and pharmaceutical wholesale, liquidity and cash flow, and inventory and availability analysis.
tiger.PHARMA: translate reference-price changes into product-code actions
tiger.PHARMA combines medicine price and product-code data with pharmacy stock, purchasing terms, turnover and liquidity. The result is a prioritised risk list, euro exposure, replenishment rules and specific clarification tasks for wholesalers or manufacturers. The objective is not a blanket stock reduction, but reliable supply with the lowest avoidable loss of value.
Official framework
- Current reference-price decisions and effective dates
- Section 35 SGB V
- BfArM reference prices and co-payments
FAQ
Does every affected pack automatically lose value?
No. Exposure depends on the product, reimbursement limit, manufacturer price, dispensing date, acquisition cost, contract, returns and credits. It must be calculated at product-code level.
Which stock should be reviewed first?
High-cost packs, slow movers, patient-specific orders without a secure dispensing date, open direct orders and items with short return windows or unclear credit arrangements.
Should pharmacies completely reduce affected stock before the effective date?
Not as a blanket rule. Security of supply and confirmed demand remain decisive. A risk-based replenishment decision should document why each relevant safety stock is retained.
How does tiger.PHARMA support pharmacies?
tiger.PHARMA builds product-code-level inventory and value analyses, connects prices with turnover and supplier terms, and creates a prioritised action plan for procurement, returns, liquidity and communication.